header logo image


Page 846«..1020..845846847848..860870..»

23andMe Wants Everyone to Get Used to Sharing Their Genetic Data – VICE

October 21st, 2019 10:43 am

This article originally appeared on VICE US.

What Anne Wojcicki, co-founder and CEO of 23andMe, would like you to consider is this: Once upon a time, people were kinda freaked out by the idea of typing their credit card info into a website. Now this is done basically all the time. Your phone is a digital wallet; your web browsers will memorize your card numbers for you. Might your bank information get cribbed or hacked? Has it already been? Yeah, probably so, but this is How We Live Now. Its weird to think it was ever not normal.

This little historic tale is how Wojcicki addresses the current hesitance a majority of people feel to submitting their genetic material to a database by spitting into a tube and mailing that tube off to a companys lab. In a brief discussion at the TIME 100 Health Summit in New York City on Thursday, Wojcicki explained that shes actually grateful for the 2030 percent of the population thats down to spit (according to a Twitter poll TIME ran ahead of Wojcickis talk). At-home DNA kits like 23andMe are still a relatively new technology. People simply need to grow accustomed to the ideas of genetic testing and sharing genomic data with public databases, so that researchers can observe patterns across the population, and ultimately make people healthier, she said.

Its essentially an argument for sharing DNA data as good for public health, like a new-age equivalent of getting vaccinated. To drive the point home further, Eric Lander, a geneticist and director of the Broad Institute of MIT (and someone who once sat around a table with Jeffrey Epstein), mentioned a potential breakthrough in treating angiosarcoma, a rare, highly fatal cancer by using using DNAthat, Lander argued, may never have happened if it werent for peoples willingness to fork over health and genetic information.

Its hard to find a sensible, non-demonic argument against something that could lead to expedited breakthroughs in cancer treatment. But what has to be kept in mind is that 23andMe is a private company. These anecdotesvirtuous as they may soundare marketing techniques. Wojcicki rightfully believes that no singular institution will be able to harvest the amount of DNA that her company has. According to 23andMes About page, more than 10 million people have spit into its tubes and thereby handed their genetic information over. Of those 10 million, 80 percent have opted in to participate in research, via that spit data. For context: The National Institute of Health is currently in the midst of enrolling its largest DNA-related study to date (All Of Us), which will reach full enrollment at one million participants. About a year into their recruiting efforts, theyre about a quarter of the way there, according to what NIH Director Francis Collins said in a separate panel at Thursdays TIME 100 Health Summit.

Wojcicki emphasized that only those who opt in for ancestry information have their data entered into public databases, which are subject to subpoena (the likes of which helped identify the Golden State Killer). She further emphasized that, because DNA is highly similar among family members, submitting your spit implicates your relatives genetic information. (23andMe consents around this.) Thats a hell of a lot of data thats sitting around for seemingly forever, and since 23andMe is, once again, a private company, theres no telling what happens to this info if/when the company goes under, or if they decide to change their policies.

What 23andMe is sitting on now is perhaps the most valuable pool of genetic data in the world. Earlier this year, the company partnered with TrialSpark, an NYC-based research company, in order to use its large database of data to fit its opted-in consumers to studies. Mind you, Wojcicki used to work on Wall Street. She is, at her core, a businessperson. Charging customers to have their data, and then partnering with another company with an interest in that data, sounds lucrative as fuck; a hell of a business deal.

Wojcicki and Lander concluded their talk on Thursday with a heartwarming sentiment: The virtue of something like 23andMe is that consumers (or participants, however youd prefer to look at it) have access to their genetic data, rather than submitting it to a study and never getting feedback. Wojcicki refers to this as empowering; its empowering to know whats going on in the little strands that make you the person you are. It also sounds very empowering, monetarily speaking, for those in the game, marketing spit kits and trading (totally consented for!!) genetic data.

More here:
23andMe Wants Everyone to Get Used to Sharing Their Genetic Data - VICE

Read More...

US Dairy Cows Are Very Genetically Similar. That’s Not Good : The Salt – NPR

October 21st, 2019 10:43 am

Unlike most dairy cows in America, which are descended from just two bulls, this cow at Pennsylvania State University has a different ancestor: She is the daughter of a bull that lived decades ago, called University of Minnesota Cuthbert. The bull's frozen semen was preserved by the U.S. Agriculture Department. Dan Charles/NPR hide caption

Unlike most dairy cows in America, which are descended from just two bulls, this cow at Pennsylvania State University has a different ancestor: She is the daughter of a bull that lived decades ago, called University of Minnesota Cuthbert. The bull's frozen semen was preserved by the U.S. Agriculture Department.

Chad Dechow, a geneticist at Pennsylvania State University who studies dairy cows, is explaining how all of America's cows ended up so similar to each other.

He brings up a website on his computer. "This is the company Select Sires," he says. It's one of just a few companies in the United States that sells semen from bulls for the purpose of artificially inseminating dairy cows.

Dechow chooses the lineup of Holstein bulls. This is the breed that dominates the dairy business. They're the black-and-white animals that give a lot of milk.

Dairy farmers can go to this online catalog and pick a bull, and the company will ship doses of semen to impregnate their cows. "There's one bull we figure he has well over a quarter-million daughters," Dechow says.

The companies rank their bulls based on how much milk their daughters have produced. Dechow picks one from the top of the list, a bull named Frazzled. "His daughters are predicted to produce 2,150 pounds more milk than daughters of the average bull," he says, reading from the website.

Farmers like to buy semen from top-ranked bulls, and the companies keep breeding even better bulls, mating their top performers with the most productive cows. "They keep selecting the same families over and over again," Dechow says.

A few years ago, Dechow and some of his colleagues at Penn State made a discovery that shocked a lot of people. All the Holstein bulls that farmers were using could trace their lineage back to one of just two male ancestors. "Everything goes back to two bulls born in the 1950s and 1960s," he says. "Their names were Round Oak Rag Apple Elevation and Pawnee Farm Arlinda Chief."

This doesn't mean that the bulls in the catalog are genetically identical. They still had lots of different mothers, as well as grandmothers. But it does show that this system of large-scale artificial insemination, with farmers repeatedly picking top-rated bulls, has made cows more genetically similar. Meanwhile, genetic traits that existed in Holstein cows a generation ago have disappeared.

"We've lost genetic variation," Dechow says. "Now, some of that variation was garbage that we didn't want to begin with. But some of it was valuable stuff."

To see what might have been lost, Dechow decided to do an experiment. He located some old semen from other bulls that were alive decades ago, with names like University of Minnesota Cuthbert and Zimmerman All-Star Pilot. You might call them heirloom bulls. The U.S. Agriculture Department keeps samples of their semen in deep-freeze storage in Fort Collins, Colo.

Dechow used that semen to impregnate some modern cows. They gave birth, and now it's possible to see some lost pieces of the Holstein family tree come to life in a barn at Penn State in the form of three cows.

Dechow leads the way to the barn. He points toward a cow that eyes us suspiciously. "Here is our old genetic lineage, [cow] number 2869," he says.

To the untrained eye, this cow looks pretty much like all the others. But Dechow sees things that others can't. "If you notice, if you look over her back see how that cow to her left is a little more bony?" he says.

Once Dechow points it out, the difference is plain to see. "So she definitely carries more body condition. She's a little bit fatter," he says.

Traditionally, dairy farmers didn't like cows with extra body fat. They thought the ideal cow was a skinny one, because she was turning all her feed into milk, not fat. So farmers chose bulls that tended to produce that kind of daughter.

"We've kind of selected for tall, thin, cows," Dechow says. "And that's a really bad combination. They're infertile, unhealthy. So we need to get away from that."

Dechow thinks the frozen semen from those long-forgotten heirloom bulls can bring back valuable genes that went missing maybe genes that would allow cows to thrive in warmer temperatures, for instance.

For this to work, though, farmers actually have to use those bulls, and they'll only do so if they're persuaded that the daughters will also produce lots of milk.

So Dechow is carefully monitoring his experimental cows. So far, he says, it's going pretty well. Two of the three cows are producing at least as much milk as the industry average.

Follow this link:
US Dairy Cows Are Very Genetically Similar. That's Not Good : The Salt - NPR

Read More...

$2.1 million drug approved for Pearland toddler with rare genetic disease – KHOU.com

October 21st, 2019 10:43 am

PEARLAND, Texas A 2-year-old whose family has been fighting for a $2 million drug to battle her rare disease received approval for the drug Friday.

Krista James has Spinal Muscular Atrophy, or SMA, a life-threatening condition that severely impacts kids muscle movements. Her family has been fighting for the toddler to receive Zolgensma, a cutting-edge gene therapy that treats the disease at the genetic level.

RELATED: Pearland family fighting to get $2.1 million drug for toddler with rare genetic disease

Zolgensma is the most expensive drug to ever receive FDA approval. The treatment is priced at $2.125 million.

Despite Kristas doctor telling Medicaid its what the toddler needs, the request for coverage was denied until Friday, which happened to be Kristas 2nd birthday. Texas Health and Human Services approved the family's appeal.

The family told KHOU 11 they are beyond blessed and considered the approval the best birthday present ever.

ALSO POPULAR ON KHOU.COM

Send us a news tip | Download our app |#HTownRush Newsletter

Continue reading here:
$2.1 million drug approved for Pearland toddler with rare genetic disease - KHOU.com

Read More...

National News Family tries to cure toddler with rare genetic disease Tomas Hoppough 9:36 AM – ABC15 Arizona

October 21st, 2019 10:43 am

A Denver family is trying to raise $3 million in order to cure their son with a rare genetic disease.

Doctors told Amber Freed that her 2-year-old son is one of 34 people in the world to have this rare neurological genetic disease.

The disease is so rare, it doesnt even have a name, Freed said. Its called SLC6A1, because that is the gene that it effects.

The disease causes Maxwell to have trouble moving and communicating, and soon it will only get worse.

The most debilitating part of the disease will begin between the ages of 3 and 4, Freed said. So, we are in a fight against time.

Maxwell has a twin sister named Riley.

I noticed early on that Maxwell wasnt progressing as much as Riley, Freed said. I noticed he couldnt use his hands. The doctors told me that every baby can use their hands. Thats when I realized there was something wrong with him.

After multiple visits to the doctor, Freed was able to find a genetic specialist to give Maxwell a diagnosis.

He looked at me and said, Something is very wrong with your son. I dont know if hes going to live, Freed said. My soul was just crushed. It was a sadness I didnt even know existed on earth. You never think something like this could happen. I left my career, and I had no other choice but to create my own miracle and to find a treatment forward to help Maxwell and all those others like him.

Freed searched for scientists trying to create a cure, which she found at the University of Texas Southwestern Medical Center in Dallas.

Were working with diseases where kids are born with a defective gene, said Steven Gray, an associate professor at UTSW in pediatrics. Our approach is to replace that gene to fix the condition at the level of their DNA. Were taking the DNA that those patients are missing and packaging that into a virus and use that virus as a molecular delivery truck to carry those genes back in their body and fix their DNA.

Its a rare disease, no one has ever heard of it, Freed said. But one rare disease messed with the wrong mother.

Freed said she has raised $1 million to help with research for the cure and will need an additional $3 million, in order to let Maxwell and many others continue to enjoy life.

I want Maxwell to have every opportunity that children should have in this life, Freed said. When he is having a good day, I just try and soak him in as much as I can. We dont take anything for granted in this house.

If you want to help donate for the cure, you can do so by visiting MilestonesforMaxwell.org or click on this GoFundMe page.

Read more here:
National News Family tries to cure toddler with rare genetic disease Tomas Hoppough 9:36 AM - ABC15 Arizona

Read More...

UCLH and UCL begin trial of genetic analysis in blood pressure patients – University College London Hospitals

October 21st, 2019 10:43 am

While this has been done as part of a number of studies in the past, the UCLH and UCL approach is unique in that they will also be returning this information to the patients as well as the doctors to understand how this information is useful and how it should be best communicated with doctors and patients.

For the UCLH BRCs AboutMe initiative, researchers will analyse patients DNA and other personal biological information to try to understand why some people have high blood pressure and others dont, and if it could be used to tailor treatment and whether it would be feasible for such testing to be rolled out across the NHS for other disease areas.

Some NHS patients have already had their DNA sequenced as part of the 100,000 Genomes Project done by Genomics England, but that project has so far focussed on rare diseases and cancer. UCLH and UCL researchers aim to extend this sequencing effort for common conditions. This effortand return of genomic information has not been done in the NHS before, within routine care.

The ultimate aim is that any NHS patient could have their DNA analysed in order to predict their chance of developing different conditions, prevent or reduce their risk of disease, and diagnose patients earlier with data returned to patients in a personalised report. Data from patients may also help in future with the development of drugs or tailoring of treatment.

For the initial study, research processes will be carried out in parallel with routine care to minimise disruption to patients. For instance, the doctor will seek the patients consent in the course of a clinic appointment, and the phlebotomist will take blood samples for research at the time of taking samples for standard tests. Blood samples will be processed by UCLHs laboratory.

The BRCs AboutMe initiative seeks to embed genomics and testing of other personal biological information into the NHS.

Researchers will be working with patients to look at how genetic information, including information on the risk of developing different conditions, can be best communicated to patients within the NHS environment.

See more here:
UCLH and UCL begin trial of genetic analysis in blood pressure patients - University College London Hospitals

Read More...

Pulse Biosciences Presents Data From Several Clinical Studies of Nano-Pulse Stimulation Technology to Clear Skin Lesions at the 2019 ASDS Annual…

October 20th, 2019 6:44 am

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company bringing to market its proprietary CellFX System harnessing Nano-Pulse Stimulation (NPS) technology, today announced that it will present results of three clinical studies demonstrating high clearance rates across its benign skin lesion portfolio during the upcoming American Society for Dermatologic Surgery (ASDS) annual meeting on October 24-27, in Chicago. The data will span the companys CellFX procedure using NPS non-thermal energy in clearing Sebaceous Hyperplasia lesions, non-genital warts and back acne. The cellular-specific NPS technology was also selected to be featured at the opening Plenary Session, which highlights cutting-edge science and emerging therapies in dermatologic surgery.

The breadth and depth of the clinical data we are presenting at ASDS points to the tremendous progress we are making collaboratively to advance our CellFX System across a broad range of benign lesions, said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. These results reflect the ongoing commitment needed to introduce the CellFX System into the clinic to improve clinical outcomes and quality of life for patients.

In prior studies, investigator assessments concluded that the NPS procedure met efficacy endpoints in 99.5% of Sebaceous Hyperplasia lesions and 82% of Seborrheic Keratosis lesions along with normal and expected skin recovery periods. NPS technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent healthy, non-cellular tissue.

Dr. Tom Rohrer, a dermatologic surgeon in private practice at SkinCare Physicians in Boston, MA, and former president of the ASDS, will spotlight NPS technology in his lecture at the Emerging Therapies plenary of the Societys annual meeting.

I am excited to share the science and clinical data on NPS technology because it is a first-of-its-kind bioelectric technology that is genuinely different from existing energy-based devices, said Thomas Rohrer, MD. In our clinical experience, as well as in peer-reviewed published studies, the cellular mechanism of NPS energy points to a rapidly evolving and dynamic new technology with a tremendous amount of upside for our patients.

ORAL PRESENTATIONS:

Abstracts

Lead Authors

Key Findings

Schedule

First Clinical Use of Non-Thermal Nano-Pulse Stimulation Technology for Treating Cutaneous, Non-Genital Warts [Feasibility Study]

E. Victor Ross, MD,Girish Munavalli, MD

The high rate of wart size reduction suggests the utility of the unique NPS cellular mechanism for the treatment of non-genital, cutaneous warts. In two instances, the control wart showed 100% reduction in size, suggesting there may be an immune response. Based on these initial results, a larger pivotal study is warranted and will be conducted in the future.

Thursday,October 24th7:30 - 8:45 amCentral Time

GeneralDermatology

Oral Abstracts

A Feasibility Study for the Treatment of Moderate to Severe Acne Vulgaris of the Back Using Nano-Pulse Stimulation Energy

Mark S. Nestor, MD,

Brian Berman, MD,Jessica Jones, DO,Taraneh Matin, DO

Initial data of two male patients suggests the positive effect of treating back acne with NPS energy. A larger study is needed to validate these promising early results and to focus on achieving similar acne lesion reduction efficacy while minimizing the rate and extent of hyperpigmentation.

ThursdayOctober 24th8:23 - 8:25 am

General DermatologyOral Abstracts

Emerging Therapies in Dermatologic Surgery

Thomas Rohrer, MD

An overview of the science, mechanism and clinical uses of Nano-Pulse Stimulation technology for clearing benign and malignant skin lesions.

Thursday,October 24th10:45a Noon

Plenary Session

A Multicenter, Pivotal Study Using the Nano-Pulse Stimulation Procedure to Treat Sebaceous Hyperplasia Lesions [Optimization Study]

Girish Munavalli, MD

Brian Zelickson, MD,Suzanne Kilmer, MD,Brenda LaTowsky, MD,

Elizabeth Tanzi, MDAva Shamban, MD

This second study of SH lesions evaluated the use of lower energy levels for relative efficacy and recovery periods, as well as lower side effect profiles.

The data reaffirms that NPS technology is an effective method for safely clearing SH lesions. The reduced energy levels utilized in this study demonstrated similar levels of efficacy as in the previous study, while reducing the time of normal skin recovery and decreasing the rate and duration of residual skin effects, such as hyperpigmentation and volume loss.

Thursday,October 24th3:00- 3:05 pm

Cosmetic DermSurgery OralAbstracts

About Pulse Biosciences

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that improves and potentially extends the lives of patients. The CellFX System is the first planned commercial product to harness the distinctive advantages of the Companys proprietary Nano-Pulse Stimulation (NPS) technology to treat a variety of applications for which an optimal solution remains unfulfilled. NPS technology delivers nano-second pulses of high amplitude electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The cell-specific effects of NPS technology have been validated in a series of ongoing clinical trials. The CellFX System is preparing to launch in 2019 as a multi-application platform designed to address a broad range of dermatologic conditions. As part of the customer experience, the Company is offering a utilization-based revenue model and easy-access customer portal offering a suite of services. CellFX procedures offer customer value across an expanding spectrum of clinical applications. The initial commercial use will be in the clearance of common and difficult to treat skin lesions that share high demand among patients and practitioners for improved and durable aesthetic outcomes that lead to greater overall satisfaction.

Caution: Pulse Biosciences CellFX System and Nano-Pulse Stimulation technology are for investigational use only.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences expectations regarding regulatory clearance and the timing of FDA filings or approvals, the mechanism of action of NPS treatments, current and planned future clinical studies, other matters related to its pipeline of product candidates, future financial performance and other future events. These statements are not historical facts but rather are based on Pulse Biosciences current expectations, estimates, and projections regarding Pulse Biosciences business, operations and other similar or related factors. Words such as may, will, could, would, should, anticipate, predict, potential, continue, expects, intends, plans, projects, believes, estimates, and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Read more here:
Pulse Biosciences Presents Data From Several Clinical Studies of Nano-Pulse Stimulation Technology to Clear Skin Lesions at the 2019 ASDS Annual...

Read More...

Healthcare Nanotechnology Market 2019 Will Generate New Growth Opportunities In The Upcoming Year | – Global Market Release

October 20th, 2019 6:44 am

The Healthcare Nanotechnology Market research report is provided with the information categorizing by parameters such as players, brands, regions, types and application. The report also illustrates the information about the global market status, competition landscape, growth rate, future trends, market drivers, challenges and opportunities and porters forces analysis with respect to these elements.

Get Sample Copy of Report Here @ https://www.reportsintellect.com/sample-request/820149

You get the detailed analysis of the current market scenario for Healthcare Nanotechnology and a market forecast till 2024 with this report. The forecast is also assist with the elements affecting the market dynamics for the forecast period. This report also details the information related to geographic trends, competitive scenarios and opportunities in the Healthcare Nanotechnology market. The report is also providing with SWOT analysis and value chain for the companies which are profiled in this report.

Key Players of Healthcare Nanotechnology Market:

AmgenStrykerTeva PharmaceuticalsUCBRocheAbbottMerck & Co

This report also covers the study relating to the key regions for the global market size for the Healthcare Nanotechnology such as North America, Europe, Asia Pacific, South America, Middle East, Africa etc. and focuses on the consumption of Healthcare Nanotechnology in these regions.

This comprehensive research covers all the important information pertaining to the Healthcare Nanotechnology market. For this study, Reports Intellect has conducted all-encompassing primary research with key players to collect first had data. Moreover, in-depth interviews with main leaders also assisted in the validation of findings from secondary research and to understand key trends in the Healthcare Nanotechnology market. Primary research makes up the main source of information gathering and validation

Segmentation by product type:NanomedicineNano Medical DevicesNano DiagnosisOther

Segmentation by application:AnticancerCNS ProductAnti-infectiveOther

Get Best Discount on Report @ https://www.reportsintellect.com/discount-request/820149

Table of Contents

2019-2024 Global Healthcare Nanotechnology Market Report (Status and Outlook)

1 Scope of the Report

1.1 Market Introduction

1.2 Research Objectives

1.3 Years Considered

1.4 Market Research Methodology

1.6 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Healthcare Nanotechnology Market Size 2014-2024

2.1.2 Healthcare Nanotechnology Market Size CAGR by Region

2.2 Healthcare Nanotechnology Segment by Type

2.3 Healthcare Nanotechnology Market Size by Type

2.3.1 Global Healthcare Nanotechnology Market Size Market Share by Type

2.3.2 Global Healthcare Nanotechnology Market Size Growth Rate by Type

2.4 Healthcare Nanotechnology Segment by Application

2.5 Healthcare Nanotechnology Market Size by Application

2.5.2 Global Healthcare Nanotechnology Market Size Growth Rate by Application (2014-2019)

Reasons Why You Should Buy This Report?

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.

So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

sales@reportsintellect.comPhone No: + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Continued here:
Healthcare Nanotechnology Market 2019 Will Generate New Growth Opportunities In The Upcoming Year | - Global Market Release

Read More...

Start-up of the week: charging your car can be done in minutes – Innovation Origins

October 20th, 2019 6:44 am

Your sneak preview of the future is the slogan of Innovation Origins, and thats just what we will highlight with our Start-up of the Week column. Over the past few days, five start-ups of the day have been featured and on Saturday we will choose the weeks winner.

Innovation Origins presents a Start-up of the Day each weekday

We shall consider various issues such as sustainability, developmental phase, practical application, simplicity, originality and to what extent they are in line with theSustainable Development Goals of UNESCO. They will all pass by here and at the end of the week, the Start-Up of the Week will be announced.

Moreover, our weekly winners may be awarded another prize. Because at the end of each calendar month, our readers, together with the editors of IO, will select the Start-up of the Month!

The way we use medicines is still somewhat primitive. Maybe thats not surprising, because our options are limited when it comes to taking medication. Most organs are well protected from the outside world. Nevertheless, this also means that medicines cannot be administered very effectively. Dosages are therefore often higher than necessary because they have to travel a long way through our bodies.

Sovigo wants to change this through nanotechnology. Their capsules are about 100 nanometres in size, which is 10,000th of a millimeter (!) The main advantage is that this nanomedicine is effective solely at the point where the medication is actually needed. Preliminary results are encouraging for treating intestinal disorders.

Climate change and dwindling agricultural land are major challenges for food and feed production. The supply of animal protein is particularly problematic.

The start-up Blue Planet Ecosystems, based in San Francisco and Vienna, wants to shift pisciculture (fish farming) to computerized container systems. The ecosystem is to be simulated in such a way that nature is able to grow in self-sustaining LARA systems (Land-based Automated Recirculating Aquaculture).

Lara Systeme (c) Blue Planet Ecosystems

This German start-ups drone system has brought a new automation revolution to warehouses. The flying assistants are able to make an inventory of a warehouse on their own by making a kind of digital impression of it. At present, maintaining a warehouse is a time-consuming task. Doks. Innovation promises a time gain of no less than 90% and a cost reduction of 80%. Data collected by the drones are subsequently made available in a proprietary data analysis system. Similar concepts are focused on a single management system as a rule, whereas Doks offers a universal system.

Giving freedom back to people who have limited freedom of movement. Thats the noble goal that former snowboarder Patrick Mayer has committed himself to. Mayer ended up in a wheelchair for a long time himself and personally experienced how winter can throw a spanner in the works. Moving through snow and over ice in a wheelchair or with crutches is just not much fun.

Which is why he came up with Wheelblades, a kind of mini-snowboard that gives more stability to the front wheels. For people on crutches, there is the SafetyFoot, an extra foothold for underneath crutches. And Wheelblades are also suitable for prams, so that you are able to go on a winter hike with your little one without any hassles.

Recharging: it is perhaps the greatest sore point that is associated with electric mobility. Compared to traditional refueling, it takes ages before you can get back on the road. If its up to the Israeli start-up Chakratec, this will soon be a thing of the past. Their kinetic battery fills up about as fast as your diesel tank does. Yet the potential is even greater: the battery has unlimited charging cycles and contains no pollutants.

They are setting their sights on a heroic reputation. A start-up for the benefit of humankind. What makes this mission even more challenging, is that the market in which they have delved into is dominated by Chinese companies. How do you stand out? The solution is simple and difficult at the same time. Come up with something completely new. The result is a kinetic battery with flywheel technology.

A battery can be highly innovative; but without a good charger it is of little use. Chakratec maintains that current infrastructure has been overwhelmed by reality and is suffering from too much red tape. It would be possible to create fast charging stations anywhere, even with a weak network, with the relevant fast charging technology.

The potential of Chakratecs technology has not gone unnoticed. The start-up has already won several awards, including one for best storage technology. They can add another feather in their cap because the favorable prospects for Chakratec make it the Start-up of the Week!

There is a frantic search going on around the world for efficient and sustainable batteries and the subject is also regularly addressed by Innovation Origins. At the beginning of this month, for example, we spoke to the start-up High Performance Battery, which is also trying to bring a new type of smartphone battery onto the market. Or does the future for cars lie with hydrogen technology? We sought answers to that question here in this series.

Innovation Origins is an independent news platform, which has an unconventional revenue model. We are sponsored by companies that support our mission: spreading the story of innovation. Read more here.

On Innovation Origins you can always read articles for free. We want to keep it that way. Have you enjoyed this article so much that you want to contribute to independent journalism? Click here:

See the article here:
Start-up of the week: charging your car can be done in minutes - Innovation Origins

Read More...

Rheumatoid Arthritis and Cognitive Impairment – Rheumatology Advisor

October 18th, 2019 6:46 pm

Adults with rheumatoid arthritis (RA) are more likely to demonstrate cognitive impairment compared with healthy adults, according to research published in the Journal of Clinical Neuroscience. Researchers highlight the potential burden of cognitive impairment in RA management.

Researchers conducted a cross-sectional, case-control study of consecutive patients to examine the prevalence of cognitive impairment and the specific factors associated with this impairment in RA.

Patients were recruited from the rheumatology unit of a university-affiliated, tertiary referral hospital between January 2016 and December 2018. Eligible patients were aged 18 years or older with an RA diagnosis based on American College of Rheumatology criteria. Patients with diagnosed dementia prior to RA diagnosis were excluded.

The final study cohort included 210 patients with RA and 70 healthy controls (83.8% and 78.6% women, respectively): Both groups were homogenous in terms of age, sex, and education level, although patients in the RA group were more likely to have hypertension, diabetes, and mood disorders.

Investigators found a statistically significant difference between the rates of cognitive impairment between the RA and control groups; 72.4% and 97.65% of patients in the RA group classified as cognitively impaired based on the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), respectively. Comparatively, only 20% and 68.6% of patients in the control group were classified as cognitively impaired (MMSE and MoCA, respectively). More patients in the RA group experienced neuropsychiatric impairment (59.5%) or subjective memory complaints (67.1%).

Mean MMSE and MoCA scores were significantly lower in patients with RA, whereas mean Hospital Anxiety and Depression Scale (HADS) Total, HADS Anxiety, and HADS Depression scores were significantly higher. Patients with RA performed significantly worse on MMSE in terms of individual analysis of cognitive domains, particularly in terms of attention, remote memory, repetition, stage command, writing, read and obey, and copy. MoCA results demonstrated statistically significant differences between RA patients and controls in almost all cognitive domains, excluding orientation.

Patients being treated with biologic therapy were less likely to be classified as cognitively impaired according to the MMSE, whereas patients treated with oral glucocorticoid therapies and those who had positive rheumatoid factor were more likely to be classified as cognitively impaired based on the MoCA.

A linear regression analysis found that Health Assessment Questionnaire results were correlated with MMSE scores, MoCA scores, and HADS scores (r=-0.21, -0.27, and 0.46, respectively). Logistic regression analyses found that patients who were older, or who exhibited their first disease symptoms at an older age, had increased odds of being classified as cognitively impaired according to the MoCA.

Limitations to the study included the cross-sectional nature of the design, meaning that despite statistical significance, the causal pathway to cognitive impairment could not be determined. Additionally, this sample is not representative of all patients with RA, and therefore results may not be generalizable.

Patients with RA may present more neurological deficits than is commonly thought, the researchers concluded. For persons with chronic diseases such as RA, intact cognitive function is critical for the successful performance of daily activities based on ones current health condition Further studies are needed to better investigate the epidemiology and the physiopathology of dementia in RA patients.

Reference

Vitturi BK, Nascimento BAC, Alves BR, de Campos FSC, Torigoe DY. Cognitive impairment in patients with rheumatoid arthritis [published online August 22, 2019]. J Clin Neurosci. doi: 10.1016/j.jocn.2019.08.027

Go here to read the rest:
Rheumatoid Arthritis and Cognitive Impairment - Rheumatology Advisor

Read More...

Increased Mortality and Seropositivity in Rheumatoid Arthritis – Rheumatology Advisor

October 18th, 2019 6:46 pm

Elevated anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF) titers have been independently associated with increased mortality in patients with rheumatoid arthritis (RA), according to research published in Arthritis Care & Research.

Researchers conducted a retrospective real-world study examining the role of ACPA and RF seropositivity in risk prediction for mortality in RA. Investigators also studied the association between ACPA and RF titers and all-cause mortality, examining whether the use of disease-modifying antirheumatic drugs (DMARDs) affected these associations.

Study data were obtained from 2 US administrative claims databases linked to laboratory data. Patients were followed from the date of the analysis-specific index until death, end of health plan enrollment, or the end of the study period (June 2016).

In total, 133,775 patients with RA were included from both databases (ACPA n=53,849; RF n=79,926). Baseline characteristics were generally balanced between groups, with DMARD use, RA diagnoses, previous or current positive smoking status, and the presence of chronic obstructive pulmonary disease significantly elevated in seropositive patients (P <.001).

The ACPA group had 184,170 patient-years of follow-up. In this group, 5.7% of patients died, and the mortality incidence rate was 16.7 per 1000 patient-years (95% CI, 16.1-17.3). The RF group had 297,830 patient-years of follow-up; 6.5% of patients died, and the mortality incidence rate was 17.5 per 1000 patient-years (95% CI, 17-18). Both ACPA and RF positivity were associated with a significant increase in mortality risk (P <.0001 for both).

In the ACPA group with baseline RF data, ACPA positivity was associated with increased mortality compared with RF positivity; double ACPA and RF positivity were associated with the highest mortality risk (hazard ratio [HR] 1.61; 95% CI, 1.45-1.79). Single ACPA positivity was associated with a higher risk compared with single RF positivity.

In the RF group with baseline ACPA data, the highest mortality risk was also noted in the ACPA and RF double-positive group (HR 1.22; 95% CI, 1.09-1.36). According to the investigators, all other combinations of the presence of ACPA and RF were associated with a significantly increased mortality risk compared with ACPA and/or RF seronegativity.

Also, mortality risk positively correlated with ACPA and RF titers and was the highest in groups of patients with the highest titers for both ACPA and RF (HR 1.60 and 1.78, respectively; 95% CI, 1.45-1.76 and 1.66-1.91). The findings were consistent when the groups were combined.

Survival curves comparing patients with ACPA and RF serostatus showed similar patterns of divergence. Compared with single ACPA and RF positivity, single ACPA and RF negativity was associated with a higher survival rate.

Both ACPA and RF single-positive patients who received conventional synthetic DMARD (csDMARD) therapies had a statistically significant increase in mortality risk (ACPA HR 1.52; RF HR 1.47). Patients who had single ACPA or RF positivity who received csDMARDs had a 46% and 62% increased mortality risk vs patients with double ACPA and RF negativity. No increase in mortality risk was noted in patients receiving biologic DMARDs.

Study limitations included those inherent to the nature of observational studies, including the absence of randomization.

Elevated ACPA and RF titers were independently associated with increased mortality among patients diagnosed with RA, the researchers concluded. Additional analyses are warranted, including evaluation of the association of disease activity and mortality.

Disclosure: This clinical trial was supported by Bristol-Myers Squibb. Multiple authors report affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Alemao E, Bao Y, Weinblatt ME, Shadick N. Association of seropositivity and mortality in rheumatoid arthritis and the impact of treatment with disease-modifying antirheumatic drugs [published online September 17, 2019]. Arthritis Care Res. doi: 10.1002/acr.24071

Read the original post:
Increased Mortality and Seropositivity in Rheumatoid Arthritis - Rheumatology Advisor

Read More...

Validation of PROMIS Pain Interference and Pain Behavior for Rheumatoid Arthritis – Clinical Pain Advisor

October 18th, 2019 6:46 pm

The PatientReported Outcomes Measurement Information System (PROMIS) is a universally applicable set of itembanks for the evaluation of patientreported health. Both the PROMIS Pain Interference (PROMISPI) and the PROMIS Pain Behavior (PROMISPB) itembanks were found to have good psychometric properties for patients with rheumatoid arthritis and to be useful as computerized adaptive tests (CATs) in clinical practice and research, according to a study published in Arthritis Care & Research.

The objective of the current study was to evaluate the psychometric properties of the PROMIS-PI and the PROMIS-PB item banks (40 and 39 items, respectively) in Dutch and Flemish patients with rheumatoid arthritis. Properties examined in those assessments are unidimensionality, crosscultural validity (Differential Item Functioning [DIF] for language [Dutch vs Flemish]), other forms of measurement invariance, floor and ceiling effects, monotonicity, Graded Response Model (GRM) fit, local dependence, construct validity, and reliability.

Both the PROMISPI and PROMISPB item-banks were found to have sufficient unidimensionality (OmegaH 0.99 and 0.95; ECV 0.95 and 0.78; respectively), to have negligible local dependence (0.3% and 1.4% of itempairs), good monotonicity (scalability coefficient of the scale, 0.75 and 0.46), and a good graded response model fit. Both item-banks also showed good cross-cultural validity (absence of differential item functioning for language), measurement invariance (absence of differential item functioning for age, sex, disease activity, and administration mode), good construct validity, high reliability (>0.90 in the range of patients with rheumatoid arthritis), and absence of floor and ceiling effects (0% maximum or minimum score for both). The PROMIS-PI correlated strongly with the Dutch-Flemish PROMIS Global Health Pain intensity (r=0.80), the Short-Form Health Survey Physical Functioning scale (r=-0.71) and the Health Assessment Questionnaire Disability Index (r=0.71). The PROMIS-PB also correlated strongly with the Dutch-Flemish PROMIS Global Health Pain intensity 266 (r=0.61). These findings add to the evidence that the PROMIS item-banks provide an adequate assessment of pain interference and behavior, respectively.

Both the PROMIS-PI and PROMIS-PB banks showed good psychometric properties in patients with [rheumatoid arthritis]. Using the highly efficient PROMIS-PI and PROMIS-PB CATs in research and clinical practice is considered to be user-friendly and feasible with little administration time, and has the potential for valid and precise standardized and routine patient monitoring of pain interference and pain behavior, concluded the study authors.

Follow @ClinicalPainAdv

Reference

Crins MHP, Terwee CB, Westhovens R, et al. First validation of the full PROMIS pain interference and pain behavior item banks in patients with rheumatoid arthritis [published online September 28, 2019]. Arthritis Care Res (Hoboken). doi: 10.1002/acr.24077

Original post:
Validation of PROMIS Pain Interference and Pain Behavior for Rheumatoid Arthritis - Clinical Pain Advisor

Read More...

Positive Opinion of Upadacitinib for Active Rheumatoid Arthritis – Pharmacy Times

October 18th, 2019 6:46 pm

The European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) agreed on a positive opinion for AbbVies upadacitinib (RINVOQ), according to the company. The JAK inhibitor is a once-daily selective treatment used for adult patients with moderate to severe active rheumatoid arthritis who are intolerant to 1 or more disease-modifying antirheumatic drugs.

CHMP's positive opinion is a scientific recommendation for marketing authorization to the European Commission, which authorizes marketing approval in the European Union. This opinion is supported by data from a global phase 3 SELECT rheumatoid arthritis program. 4400 patients with moderate to severe active rheumatoid arthritis were evaluated in 5 different trials, including SELECT-NEXT, SELECT-BEYOND, SELECT-MONOTHERAPY, SELECT-COMPARE, and SELECT-EARLY.

All primary and secondary endpoints were met, including low disease activity based on Disease Activity Score 28 C-Reactive Protein. Improved response was seen with upadacitinib, both as a monotherapy and in combination with conventional synthetic DMARDs compared to placebo.

The SELECT program showed a consistent safety profile across all five studies, with the most frequent adverse reactions being infections.

REFERENCE

AbbVie receives chmp positive opinion for upadacitinib (rinvoq) for the treatment of adults with moderate to severe active rheumatoid arthritis [news release]. North Chicago, Ill.; PR Newswire: October 18, 2019. https://www.prnewswire.com/news-releases/abbvie-receives-chmp-positive-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis-300940994.html. Accessed October 18, 2019.

More:
Positive Opinion of Upadacitinib for Active Rheumatoid Arthritis - Pharmacy Times

Read More...

Top 9 Drugs With the Biggest Price Increases Over 2 Years – Pharmacy Times

October 18th, 2019 6:46 pm

Nine widely-used medications have experienced substantial price surges over the past 2 years, adding $5.1 billion to overall drug spending during this time period, according to a new report.

Furthermore, 7 of these 9 drugs were found by the Institute of Clinical and Economic Review (ICER) to be lacking sufficient clinical evidence to support such price increases. Not only did adalimumab top the list of best-selling drugs last year, but the anti-inflammatory medication ranked first in terms of the most substantial price hikes from 2016 to 2018.

Of the drugs listed, the ICER indicated that lenalidomide and dimethyl fumarate were the only 2 with new clinical evidence. However, the report noted that this is not a determination that the new evidence necessarily justified these prices increases.

Below are the top 9 drug price hikes based on wholesale acquisition cost (WAC) increase, net price increase, and overall estimated increase in drug spend.

1.Adalimumab (Humira)

WAC increase: 19.1%Net Price increase: 15.9%Drug spending increase: $1.86 billion

Indicated for: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, adult and pediatric Crohn disease, ulcerative colitis, plaque psoriasis, adult and adolescent hidradenitis suppurativa, and adult and pediatric non-infectious uveitis.

2.Rituxan (rituximab)

WAC increase: 17%Net Price increase: 23.6%Drug spending increase: $806 million

Indicated for: non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, pemphigus vulgaris, granulomatosis with polyangiitis, and microscopic polyangiitis.

3. Pregabalin (Lyrica)

WAC increase: 28.3%Net Price increase: 22.2%Drug spending increase: $688 million

Indicated for: Neuropathic pain associated with diabetic peripheral neuropathy, neuropathic pain associated with spinal cord injury postherpetic neuralgia, adjunctive therapy for partial-onset seizures in patients 1 month of age and older, and fibromyalgia.

4. Elvitegravir, Cobicistat, Emtricitabine, Tenofovir (EVG/COBI/FTC/TAF) (Genvoya)

WAC increase: 14.3%Net Price increase: 21.7%Drug spending increase: $651 million

Indicated for: HIV in antiretroviral (ART)-nave adults and pediatric patients aged 12 years and older and to replace the current ART regimen in virologically suppressed patients.

5. Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada)

WAC increase: 14.3%Net Price increase: 23.1%Drug spending increase: $550 million

Indicated for: to be used in combination with other antiretroviral agents for the treatment of HIV-infected adults and childred aged 12 yeas and older and for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adulst and adolescents at high risk.

5. Pegfilgrastim (Neulasta)

WAC increase: 14.6%Net Price increase: 13.4%Drug spending increase: $489 million

Indicated for: decrease the incidence of infection as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia and to increase survival in patients acutely exposed to myelosuppressive doses of radiation.

6. Tadalafil (Cialis)

WAC increase: 26.2%Net Price increase: 32.5%Drug spending increase: $403 million

Indicated for: erectile dysfunction and benign prostatic hyperplasia

7.Dimethyl Fumarate (Tecfidera)

WAC increase: 16.7%Net Price increase: 9.8%Drug spending increase: $313 million

Indicated for: relapsing forms of multiple sclerosis

8.Lenalidomide (Revlimid)

WAC increase: 25.8%

According to the report, ICER received public comment that lenalidomide experienced important price increases, but due to uncertainties in the volume of unit sales, they were unable to accurately determine the change in drug spending.

Indicated for: myelodysplastic syndromes, mantle cell lymphoma that has relapsed or progressed after 2 prior therapies, and multiple myeloma.

Reference

Institute for Clinical and Economic Review. Unsupported Price Increase Report. October 8, 2019.https://icer-review.org/wp-content/uploads/2019/01/ICER_UPI_Final_Report_and_Assessment_100819_Final.pdf. Accessed October 9, 2019.

View original post here:
Top 9 Drugs With the Biggest Price Increases Over 2 Years - Pharmacy Times

Read More...

US Survey Finds 60% of Americans Struggle to Afford Medications for JA, Other Rheumatic Diseases – Juvenile Arthritis News

October 18th, 2019 6:46 pm

Nearly 60% of respondents in a national survey of people with juvenile arthritis and other rheumatic diseases reported struggling to afford their medications in the past year.

The online survey, conducted by the American College of Rheumatology (ACR) in June, with the results recently released, included 1,517 adults living in the U.S. Participants were asked about their lifestyle, access to healthcare, and its affordability.

Results showed that although most of the respondents (90%) had health insurance coverage, nearly 60% had difficulties affording their treatments.

Nearly half reported that insurance companies impose a step therapy, in which patients must take and fail to respond to an insurer-preferred treatment before they are covered for therapy options prescribed by their doctors. This occurred even when a patients doctor doubted the efficacy of the insurer-preferred option.

Out-of-pocket costs greater than $1,000 a year were reported by one in four of the respondents. In 6% of the cases, yearly out-of-pocket costs skyrocketed to over $5,000.

While more than 50% of the respondents are currently followed by or have been referred to a rheumatologist, the waiting period before a first consultation was more than 30 days in approximately 60% of the cases.

Nearly two-thirds of patients (63.81%) reported impairments to their daily lives, with the disease affecting their ability to perform simple tasks such as eating, getting dressed, cooking meals, or running errands.

These findings make clear that Americans living with rheumatic disease regardless of age, gender, or income level struggle to find affordable care, Paula Marchetta, MD, president of the American College of Rheumatology, said in a press release.

To address these challenges, it is crucial for patients, clinicians, and policymakers to work together to improve access to rheumatology care so that patients can live longer, healthier, and more fulfilling lives, Marchetta added.

Together with people with rheumatology, ACR staffers recently attended the annual Advocates for Arthritis event at Capitol Hill, to push for changes to legislation. Specifically, the advocates urged for a stop in the excessive use of step therapy by insurance companies and for legislation that would increase the number of rheumatologists.

The 2019 survey followed last years 2018 ACR survey, which asked patients from all 50 states and the District of Columbia, How easy is it to live with rheumatic disease in my state? This years assessment adds further information on the challenges faced by people diagnosed with a rheumatic disease.

According to the Centers for Disease Control and Prevention, nearly one in four Americans have a rheumatic disease, which includes juvenile arthritis, rheumatoid arthritis, systemic lupus erythematosus, and Sjgrens syndrome. As as many as 300,000 children in the country are estimated to have juvenile arthritis.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Total Posts: 11

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

See the original post here:
US Survey Finds 60% of Americans Struggle to Afford Medications for JA, Other Rheumatic Diseases - Juvenile Arthritis News

Read More...

New Study Adds Concern That Medication To Treat Painful Bladder Condition Linked To Vision-Threatening Eye Condition – Forbes

October 18th, 2019 6:45 pm

Age-related macular degeneration with neovascularization of torn and rolled-up retinal pigmented ... [+] epithelium. (Photo By BSIP/UIG Via Getty Images)

Evidence continues to mount that a drug commonly prescribed for decades to treat a painful bladder condition known as interstitial cystitis (IC) is linked to retinal damage and toxicity. The retina is the light-sensing tissue at the back of the eye that allows us to see our world.

A 2018 study by Nieraj Jain, M.D, Assistant Professor of Ophthalmology, Emory University School of Medicine, Emory Eye Center, reported reading difficulty and visual changesespecially under dark conditionsamong six patients who had been taking the drug, Elmiron (pentosan polysulfate sodium, PPS) for an average of 15 years (range of 12-20 years).

Jain found that this group of six patients (median age 60; age range 37-62) all had atypical changes in their macula, the central part of the retina that allows us to have clear central vision. The patients described difficulty reading in dim light and diminished central visual acuity. The patients underwent genetic testing to determine if there was any basis for hereditary retinal loss, with none demonstrating any such evidence of a link. Other than Elmiron, there was no clear etiology based on other findings in their medical history that explained the concerning retinal changes found in all six patients. This led the researchers to issue a warning in 2018 that long-term use of Elmiron could potentially lead to retinal damage.

An additional 10 patientsage range of 38-68 years of agewith similar retinal changes were also reported by the same researchers in May of 2019, and presented at the 2019 annual meeting of the American Urological Association. The authors concluded that structural changes in the retina were certainly present, stating that it was unclear if stopping the medication would reverse the noted changes.

This ongoing concern led researchers from Kaiser Permanente in Northern California to study this phenomenon further in their own patients taking this medication.

They found that about 25% of their patients with significant exposure to Elmiron showed clear evidence of retinal damage. The concern is that toxicity from this medication could also appear to mimic other well-known retinal conditions, such as age-related macular degeneration (AMD) or an uncommon retinal condition known as pattern dystrophy.

The research was presented last week at AAO 2019, the 123nd Annual Meeting of the American Academy of Ophthalmology.

Interstitial cystitis (IC) is a cause of unrelenting pain in the bladder and pelvic regions of the lower abdomen. Its estimated that at least 1 million people, mostly women, in the U.S. have thispainful condition. While other pharmacologic (NSAIDS, antihistamines, bladder installation therapy) and behavioral approaches are available, Elmiron is the only FDA-approved medication to treat this painful and disabling condition. It effectively works by forming a protective coating on the inner lining of the bladder that reduces irritation by substances present in the urine. Since its a first-line drug used for many decades, its believed that at least several hundred of thousand people have likely been exposed to the drug.

Robin A. Vora, M.D., Consultant in Medical Retina, Chair of Ophthalmology, Kaiser Permanente, Northern California and colleagues (Amar Patel, M.D., and Ronald Melles, M.D.) described a woman on long-term Elmiron who was misdiagnosed as having a retinal dystrophy, a genetic cause of progressive vision loss that may lead to permanent blindness. As a result of their concern that more patients that could be affected, they decided to evaluate all 4.3 million Kaiser patients.

Searching the database, they identified 140 patients who had each taken an average of 5,000 pills over a period of 15 years. Ninety-one patients of the 140 were evaluated. The investigators captured retinal images and rated them as normal, possible abnormality, or definite abnormality. The toxicity involved specialized cells known as retinal pigmented epithelium (RPE) that help nourish precious vision-producing cells in the retina known as the macula. Twenty-two of the 91 patients showed clear signs of drug toxicity. The rate of toxicity increased with the amount of drug taken, from 11% of those taking 500 to 1,000 grams to 42% of those taking 1,500 grams or more.

Its unfortunate, said Vora. You have a patient with a chronic condition like interstitial cystitis, for which there is no cure and no effective treatment. They get put on these medications because its thought to have few side effects and few risks, and no one thinks about it again year after year, the number of pills theyre taking goes up and up.

Since there is no comprehensive data yet available to guide treatment, Vora recommends patients who are asymptomatic and show no retinal signs of toxicity be screened for retinal damage at least annually. Patients who are showing signs of toxicity need to have a conversation with their health care provider whether to stop taking the medication.

Urologists and gynecologists are the primary medical providers for patients with IC. Elizabeth Kavaler, M.D., a urologist with Lenox Hill Hospital in New York City, suggested active retinal surveillance of patients would be prudent in managing patients with IC.

The impact of IC on the life of people who suffer with it cannot be minimized, she said. For women who have had good success with Elmiron, and are able to live their lives without chronic, unremitting pain, perhaps yearly or biyearly retinal exams should be done.

The mechanism behind the toxicity is unclear, but may involve the production of a toxic metabolite of Elmiron. Jains team has suggested that a component of Elmiron, a glycosaminoglycan (GAG) with a highly negative charge, may also play a potential role in disrupting the interphotoreceptor matrix in the macula. Other research by Singh and colleagues from Cleveland Clinic has suggested that Elmiron acts as an antagonist of signaling pathways related to fibroblast growth factor (FGF), a protein integral to retinal maintenance and function. There is no research that has yet elucidated the exact mechanism.

Jain has been in contact with the FDA, which is aware of his and other research linking Elmiron to retinal damage. To date, the FDA has not taken any action or issued any alerts regarding the toxicity of the medication.

The researchers are expressing growing concern that the presentation of these patients is unique and does not resemble any other identified acquired or hereditary maculopathy. At this time, an association or link with PPS exposure and maculopathy exists, but no definitive cause and effect relationship. The broader question is whether visual problems may be an unrecognized effect of IC; there have been no studies to link these two conditions as of yet.

If the changes are picked up early, its unclear whether retinal damage is reversible by discontinuing the medication. Long term monitoring will be required to make this clinical determination. For those with no clear evidence of damage who are currently taking the medication, close monitoring is critical, according to Vora and Jain. However, in later stages, toxicity can resemble late-stage dry atrophic age-related macular degeneration (AMD) and result in permanent vision loss.

Here is the original post:
New Study Adds Concern That Medication To Treat Painful Bladder Condition Linked To Vision-Threatening Eye Condition - Forbes

Read More...

2019 Celibate Clergy Candidates for Election to the Episcopacy – Official Documents – Greek Orthodox Archdiocese of America

October 18th, 2019 6:44 pm

2019 Celibate Clergy Candidatesfor Election to the Episcopacyof the Greek Orthodox Archdiocese of America

Updated on Oct.17, 2019

Download as PDF

Current Assignment: Transfiguration Of Christ Church, Mattituck, NYDirect Archdiocesan District

Date of birth: May 15, 1968Education: B.A., Hellenic College, Brookline, MA (1990)M.Div., Holy Cross, Brookline, MA (1993)

Ordinations/OffikionTo Diaconate: April 19, 1995To Priesthood: June 18, 1995Archimandrite: August 5, 2018

Current Assignment: Holy Cross Church, Whitestone, NYDirect Archdiocesan District

Date of birth: August 18, 1969Education: B.S., Computer Technology, Northeastern University, Boston, MA (1994)M.Div., Holy Cross, Brookline, MA (2004)

Ordinations/OffikionTo Diaconate: August 17, 2003To Priesthood: August 24, 2003Archimandrite: April 15, 2006

Current Assignment: Chancellor, Metropolis of Chicago

Date of birth: October 4, 1952Education: B.A., Hellenic College, Brookline, MA (1975)M.Div., Holy Cross, Brookline, MA (1978)

Ordinations/OffikionTo Diaconate: Sep. 14, 1980To Priesthood: October 5, 1980Archimandrite: May 12, 1985

Current Assignment:Saint John the Baptist Church, New York, NYDirect Archdiocesan District

Date of birth: November 15, 1945Education: A.A., Philosophy/Psychology, Kingsborough Community College, Brooklyn, NY (1992)B.A., Byzantine & Modern Greek Studies, Queens College, Queens, NY (1998)M.Div., Holy Cross, Brookline, MA (2005)

Ordinations/OffikionTo Diaconate: March 27, 2005To Priesthood: September 18, 2005Archimandrite: January 7, 2012

Current Assignment:Saint George Cathedral, Philadelphia, PAMetropolis of New Jersey

Date of birth: September 4, 1964Education: Lic., Theology, Aristoteleion University, Thessaloniki, GR (1991)M.A. Theology, Belford University School of Theology, Humble, TX (2008)M.A. Theology, Aristoteleion University, Thessaloniki, GR (2014)M.A. Ecclesiastical History, Seton Hall University-Immaculate Conception Theological Seminary (2015)PhD. Aristoteleion University, Thessaloniki, GR (2018)

Ordinations/OffikionTo Diaconate: November 24, 1985To Priesthood: January 12, 1992Archimandrite: January 12, 1992

Current Assignment:Saint George Church, Downey, CAMetropolis of San Francisco

Date of birth: August 13, 1957Education:strong> B. S., Biology, University of Richmond, VA (1979)M.S., Biology, University of Richmond, VA (1981)M.Div., Holy Cross, Brookline, MA (1987)

Ordinations/OffikionTo Diaconate: December 14, 1991To Priesthood: December 15, 1991Archimandrite: July 23, 1995

Current Assignment:Hellenic College/Holy Cross, Brookline, MADirect Archdiocesan District

Date of birth: June 7, 1954Education: M.Div., Holy Cross, Brookline, MA (1979)M.A., Byzantine History, Penn State, PA (1986)Ph.D., Byzantine History, Penn State, PA (1992)

Ordinations/OffikionTo Diaconate: December 9, 1979To Priesthood: December 23, 1979Archimandrite: May 16, 1998

Current Assignment: Saint George Church, Piscataway, NJMetropolis of New Jersey

Date of birth: December 4, 1964Education: B.A., Modern Languages, Citadel University, Charleston, SC (1987)M.Div., Holy Cross, Brookline, MA (1990)

Ordinations/OffikionTo Diaconate: February 2, 1991To Priesthood: May 11, 1996Archimandrite: May 11, 1996

Current Assignment: Kimisis Tis Theotokou Church, Brooklyn, NYDirect Archdiocesan District

Date of birth: September 11, 1944Education: B.A., Hellenic College, Brookline, MA (1973)M.Div. and S.T.M., Holy Cross, Brookline, MA (1974)

Ordinations/OffikionTo Diaconate: May 6, 1973To Priesthood: November 4, 1974Archimandrite: May 21, 1980

Current Assignment: Saints Constantine & Helen Church, Palos Hills, ILMetropolis of Chicago

Date of birth: April 14, 1967Education: B.A., Hellenic College, Brookline, MA (1985)M.Div., Holy Cross School of Theology, Brookline, MA (1992)

Ordinations/OffikionTo Diaconate: December 19, 2010To Priesthood: March 20, 2011Archimandrite: January 6, 2017

Current Assignment: Saint Barbara Church, Durham, NCMetropolis of Atlanta

Date of birth: March 9, 1957Education: B.A., Hellenic College, Brookline, MA (1980)M.Div., Holy Cross, Brookline, MA (1983)

Ordinations/OffikionTo Diaconate: September 14, 1986To Priesthood: October 19, 1986Archimandrite: June 6, 1999

Current Assignment: Saint Nicholas Church, Oak Lawn, ILMetropolis of Chicago

Date of birth: January 22, 1976Education: B.A., Hellenic College, Brookline, MA (2003)M.Div., Holy Cross, Brookline, MA (2006)

Ordinations/OffikionTo Diaconate: July 2, 2006To Priesthood: December 3, 2006Archimandrite: December 6, 2016

Current Assignment: Annunciation Cathedral, Baltimore, MDMetropolis of New Jersey

Date of birth: July 30, 1965Education: B.A., Hellenic College, Brookline, MA (1992)M.Div., Holy Cross, Brookline, MA (1994)

Ordinations/OffikionTo Diaconate: February 11, 1996To Priesthood: June 9, 1996Archimandrite: August 4, 2002

Current Assignment: Holy Apostles/Saints Peter & Paul Church, Haverhill, MAMetropolis of Boston

Date of birth: August 5, 1965Education: B.A., Hellenic College, Brookline, MA (1987)M.Div., Holy Cross, Brookline, MA (1990)ThD., Aristotelion University (2017)

Ordinations/OffikionTo Diaconate: January 30, 1991To Priesthood: February 17, 1991Archimandrite: December 31, 1996

Current Assignment: Holy Trinity Cathedral, Salt Lake City, UTMetropolis of Denver

Date of Birth: August 25, 1969Education: B.A., Hellenic College, Brookline, MA (1996)M.Div., Holy Cross, Brookline, MA (1999)

Ordinations/OffikionTo Diaconate: September 14, 1999To Priesthood: December 5, 1999Archimandrite: March 24, 2004

Current Assignment: Transfiguration of Christ Church, Corona, NYDirect Archdiocesan District

Date of Birth: October 11, 1964Education: B.A., Political Science, New York Institute of Technology, New York, NYCertificate, Antiochian House of Studies (2010)M.Div., Holy Cross, Brookline, MA (2015)

Ordinations/OffikionTo Diaconate: November 13, 2010To Priesthood: August 6, 2015Archimandrite: November 30, 2015

Current Assignment: Unassigned

Date of birth: January 1, 1958Education: M.A., Church Services, Hellenic College, Brookline, MA (1986)M.Div, Holy Cross, Brookline, MA (2007)After Hellenic College (1986) he traveled to the Monastery of Archangel Michael, Rhodos, where he was tonsured a monastic on October 21, 1991.

Ordinations/OffikionTo Diaconate & Priesthood: October 11, 1992 (Monastery of Archangel Michael, Rhodos)Archimandrite: October 20, 1994 (Church of St. Gerasimos, Pylona, Rhodos)NOTE: In 2015 incardinated into the Greek Orthodox Archdiocese of America from the Greek Orthodox Archdiocese of New Zealand. (Note: The number of years of service listed in the GOA Charter is no less than 5 years in the GOA.)

Current Assignment: Saint Demetrios Cathedral, Astoria, NYDirect Archdiocesan District

Date of birth: June 6, 1967Education: B.S., Electrical Engineering, Polytechnic University, NYC (1990)M.S., Electrical Engineering, Polytechnic University, NYC (1995)M.Div., St. Vladimirs Seminary, Crestwood, NY (2000)

Ordinations/OffikionTo Diaconate: June 16, 2002To Priesthood: January 18, 2004Archimandrite: January 18, 2004

Current Assignment: Three Hierarchs Church, Brooklyn, NYDirect Archdiocesan District

Date of birth: July 23, 1940Education: B.A., St. Johns University, Queens, NY (1962)M.Div., Holy Cross, Brookline, MA (1966)Lic., Theology, Aristotelion University, Thessaloniki, GR (1974)Diploma, Theology, Ecumenical Institute at Bossey, University de Geneve (1975)

Ordinations/OffikionTo Diaconate: January 30, 1966To Priesthood: May 29, 1966Archimandrite: May 29, 1971

Current Assignment: Lay Profession (Opthalmologist)Metropolis of New Jersey

Date of birth: April 22, 1977Education: B.A., Biology, Cornell University, Ithaca, NY (1998)MS, Science, SUNY, New York, NY (2003)O.D., Opthalmology, SUNY, New York, NY (2003)M.Th., St. Vladimirs Orthodox Seminary, Yonkers, NY (2010)

Ordinations/OffikionTo Diaconate: December 27, 2010To Priesthood: March 6, 2016Archimandrite: December 24, 2016

Current Assignment: Saints Constantine & Helen Church, Boise, IDMetropolis of Denver

Date of birth: November 7, 1945Education: Diploma*, Theology, St. Tikhons Seminary, South Canaan, PA (1973)B.A., Sociology, Kings College, Wilkes-Barre, PA (1974)* St Tikhons was granted the right to confer the M.Div. in 1988

Ordinations/OffikionTo Diaconate: December 21, 1975To Priesthood: October 3, 1976Archimandrite: November 4, 2001

Current Assignment: Saint George Cathedral, Manchester, NHMetropolis of Boston

Date of birth: April 21, 1957Education: B.S., Business Administration, Western New England College, Springfield, MA (1979)M.Div., Holy Cross, Brookline, MA (2005)

Ordinations/OffikionTo Diaconate: August 22, 2004To Priesthood: May 15, 2005Archimandrite: January 10, 2010

Current Assignment: Saint Anna Church, Roseville, CAMetropolis of San Francisco

Date of birth: September 20, 1971Education: B.A., Hellenic College, Brookline, MA (1993)M.Div., Holy Cross, Brookline, MA (1996)M.S., Science, Northeastern University, Boston, MA (1996)

Ordinations/OffikionTo Diaconate: November 17, 1996To Priesthood: February 2, 1997Economos: July 25, 2013

( )

. . (). . (). . (). . (). . (). . (). . (). . ()

. . (). . (). . (). . ()

, . . (). . (). . (). . (). . (). . (Katre)

Read the original post:
2019 Celibate Clergy Candidates for Election to the Episcopacy - Official Documents - Greek Orthodox Archdiocese of America

Read More...

Ambulatory Healthcare IT Market Trends, Syndicated Reports With AmSurg Corp, Surgical Care Affiliates, Surgery Partners, Healthway Medical Group,…

October 18th, 2019 6:44 pm

Ambulatory Healthcare IT Market report uses a range of steps for collecting, recording, analysing and interpreting market data to make this report all-inclusive. market report also endows with the list of the leading competitors and their moves such as joint ventures, acquisitions, and mergers etc.

Ambulatory Healthcare IT Market research report study presents data corralled through primary and secondary research methodologies exploring the global market. The detailed data provided in the report and the industry standard models use to analyze it make this industry report highly beneficial for the clients. This Ambulatory Healthcare IT Market research report describes the market in detail in terms of economics and regulatory factors that are currently shaping the markets growth trajectory, the regional segmentation of the global market and an analysis of the markets downstream and upstream value and supply chains are also included in the report.

Get Sample Report With All Graphs & Charts: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-ambulatory-healthcare-market

Ambulatory care is also referred as outpatient care. It is a medical care given on outpatient criteria such as consultation, rehabilitation, observation, intervention, diagnosis, and treatment services. Ambulatory care involves emergency care, primary care, ambulatory services, and others. In this intervention and surgery, overnight hospital stay is not required.

The Ambulatory Healthcare IT Market research report provides the comprehensive and in depth study of the market which sheds light on each segment and provides precise investigation considering attractiveness, demand production and sales volume and growth prospects. Moreover this Ambulatory Healthcare IT Market report features the segmentation analysis to facilitate clients with a shrewdness that helps them to select appropriate segments of the Ambulatory Healthcare IT Market

Global Ambulatory Healthcare IT Market By Type (Ambulatory Services, Primary Care Offices, Outpatient Departments, Emergency Departments, Surgical Specialty, Medical Specialty, Others), Modality (Hospital-affiliated, Freestanding), Surgery Type (Opthalmology, Orthopedics, Gastroenterology, Pain Management, Others), Application (Laceration Treatment, Bone Fracture Treatment, Emergency Care Service, Trauma Treatment), Geography (North America, South America, Europe, Asia-Pacific, Middle East & Africa) Industry Trends and Forecast to 2026

Avail The TOC Here, To Get Premium Insights About The Ambulatory Healthcare IT Market Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-ambulatory-healthcare-market

Few of the major market competitors currently working in the global ambulatory healthcare IT market are AmSurg Corp, Surgical Care Affiliates, Surgery Partners, Healthway Medical Group, SurgCenter, Trillium Health Partners, Medical Facilities Corporation, Nueterra Capital, Aspen Healthcare, Suomen Terveystalo Oy, IntegraMed America, Inc., SHERIDAN HEALTHCARE, NueHealth, Athenahealth, GENERAL ELECTRIC, Optum, Inc., Apria Healthcare Group, Inc., DaVita Inc., LVL Medical, Fresenius Kabi AG, Sonic Healthcare among others.

Summary of the research report

Want Full Report? Make Enquiries: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-ambulatory-healthcare-market

About Us

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing Corporatesales@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.comhttps://databridgemarketresearch.com

Read more from the original source:
Ambulatory Healthcare IT Market Trends, Syndicated Reports With AmSurg Corp, Surgical Care Affiliates, Surgery Partners, Healthway Medical Group,...

Read More...

Deepak Chopra Has Never Been Sick – The New Yorker

October 18th, 2019 6:44 pm

Deepak Chopra, the doctor and self-help guru, who turns seventy-three next week, has written more than one book for every year he has been alive. Chopra was born in New Delhi and studied medicine in India before moving to the United States, in 1970. After practicing as an endocrinologist in Massachusetts, he became involved in the Transcendental Meditation movement. He eventually relocated to the West Coast, left T.M. behind, and became a spiritual adviser to Michael Jackson and other celebrities. A quarter century later, his books have sold millions of copies, and his television appearancesespecially alongside Oprah Winfreyhave made him perhaps the most prominent advocate for alternative medicine recognizable around the world.

Chopras work evinces a consistent skepticism toward the scientific consensushe has called into question whether evolution is merely a process of the mindand a firm belief that mental health can determine physical reality. He has written of a place called perfect healththe title of one of his books, and now the slogan for one of his wellness retreatsin which human beings can go somewhere internally that is free from disease, that never feels pain, that cannot age or die. These beliefs have made him controversial among doctors and scientists. In 1998, Chopra was awarded the satirical Ig Nobel Prize for his unique interpretation of quantum physics as it applies to life, liberty, and the pursuit of economic happiness. A random Chopra-quote generator is popular online, and Chopra has been called out for tweeting and writing phrases that, in the words of one paper, may have been constructed to impress upon the reader some sense of profundity at the expense of a clear exposition of meaning or truth. (Example: Attention and intention are the mechanics of manifestation.)

Chopras latest book is Metahuman: Unleashing Your Infinite Potential, and it touches on a number of themes that have been present throughout his career: that human beings can become metahuman by reaching a new place of awareness; that science has served to block the way to the absolute freedom that metahuman holds out; and that self-improvement can move creation itself. I recently spoke by phone with Chopra. During our conversation, which has been edited for length and clarity, we discussed controversial remarks he has made about cancer and AIDS, his claim to have never been even a tiny bit sick, and whether there is a reality that exists independently of our own minds.

How do you define yourself and what you do?

I would say that to define oneself is to limit oneself. But Ive had various roles through my life. Im an internist, an endocrinologist, a neuro-endocrinologist; a teacher of integrative medicine and an author; a husband, a son, a father, a child.

I know you are a doctor, but does thinking about yourself as a doctor seem limiting to you in some way?

It seems limiting to me, but I would say I think of myself closer to a healer. Because, when I look at healing and the origins of the word healing, its related to the word whole. So wholeness means everything, including body, mind, and spirit, and the environment. I think of myself as a doctor who is interested in the physical body, but also in all aspects of human experiencehuman emotions, human thinking, human experience, and, ultimately, in understanding ourselves beyond the conditioned mind. So I would say I want to be a healer. Thats my aspiration.

At what point in your career did you become famous?

Some people think it happened with The Oprah Winfrey Show, in 1993, when she did a one-to-one with me for a book called Ageless Body, Timeless Mind, which then stayed on the New York Times best-seller list for thirty-some weeks. Actually, my most well-known book is The Seven Spiritual Laws of Success. But I have to say that Oprah helped me a lot with the launch of my career, and shes been an ally ever since. Weve taught six million people meditation online together.

How many books have you written now?

This is my ninetieth book.

Would you say your writing process has changed between your first and your ninetieth?

Yes. My process was more structured in the past. And now I feel its more a flow than anything else. I used to always be told by media and publishers, and even the BBC when I was in England, to dumb everything down, and I used to, and I dont anymore. I feel free to say whatever I want to.

Ive been looking for a through line in your work, and the one that Ive noticed most is the idea that our minds can determine reality, or that theres a connection between our minds and reality. Is that a fair way of phrasing it?

Yes. The correct phrase would be that our experience of the world, and of our body, is a projection of our conditioned mind. So, when youre born, you have no human constructs. Youre looking at the world as a messy, gooey experience of color, form, shapes, sounds, pictures, smells, tastes, and random thoughts, which are yet not clear. But then a construction process begins. And so youre told, Youre male, youre of a religious background, ethnic background, nationality, gender. And that begins to create a provisional identity. And then that provisional identity has perceptual experiences but interprets them as the physical body and the world. But, in the deeper reality, theres no such thing. All there is is consciousness experiencing itself perceptually, as perceptual activity, which is species-specific. You dont see the same world as a painted lady, a species of butterfly that smells the world with an antenna, tastes the world with her feet. So what is the picture of the world to a snake that navigates through the experience of infrared?

If you and a snake perceive the world differently and experience it differently, does that mean that the world is actually different? Or does it just mean that we perceive it differently?

We can only experience a narrow band with our perceptual reality. So there is no such thing as a physical world. Thats where Im going. Our experience of the world is species- and culture-specific. And that is what we interpret as fundamental reality.

You once said, Consciousness is key to evolution and we will soon prove that. What did you mean?

You know, Ive said in the past that Darwinian evolution is a human constructthat, ultimately, consciousness drives at least human evolution. We can direct our evolution by the choices we make. And now that we know the science of epigenetics and neuroplasticity, we can see very clearly that, because we are self-aware, unlike other species, we can consciously direct our evolution. And that is what epigenetics and neuroplasticity are showing us.

Epigenetics is not that we can direct our evolution, though, is it?

Well, we can trigger the activity of certain genes and decrease the activity of certain other genes. So, when people practice self-reflection or mindful awareness, or they have the experience of transcendence, you can actually see which genes get activated and which genes get deactivated. Theres a mechanism to that. So you can actually activate the genes that cause self-regulation or homeostasis, and actually decrease the activity of the genes that cause inflammation. So what is healing? It is nothing but self-regulation or homeostasis. And what is disease is mostly linked to chronic inflammation. Only five per cent of disease-related gene mutations are fully penetrant, which means they guarantee the disease. That includes everything, from Alzheimers to cancer to autoimmune disease. Only five per cent is related to genetic determinism. The rest is influenced by life style. [Gerard Karsenty, the chair of the Department of Genetics and Development at Columbia University Irving Medical Center, says, Those assumptions include non-Mendelian diseases. It is for now hard to precisely assess in multigenic diseases the extent of the contribution of gene mutations and the one of lifestyle taken in a broad sense. This is particularly true for autoimmune diseases that hit at all ages, including during childhood and with a higher incidence in women.]

You tweeted, An emerging view, alternate to Darwins random mutations & natural selection is that consciousness may be the driver of complexity/evolution.

Correct. But there are a few people who agree with that.

So, you know, scientists generally are nave realists. Which means they look at the picture of the world, and thats what it is.

What do you do, if not that?

Ive become aware of that which is having the experience rather than the experience, which in spiritual traditions is called the self. The body, the mind, and the world are the self.

It seems like all of these things are fitting under the rubric of what we were talking about earlier about consciousness and reality. I know you once said something like, The moon doesnt exist unless someone sees it. Is that right?

No, no. That was Einsteins quote, by the way. He actually said, I refuse to believe that the moon doesnt exist if no one is looking at it. [In his biography of Einstein, Abraham Pais recounted an interaction he had with the physicist who asked me if I really believed that the moon exists only if I look at it.] Thats a statement coming from a nave realist. The moon that you and I see is a human experience. A horseshoe crab doesnt have that experience living in the depths of the ocean.

Einstein was incredulously asking someone whether they really believe that the moon only exists when its looked at. Correct?

Yes. The moon is an experience in human consciousness. The moon that you and I see is an experience in human consciousness. If there was no human consciousness, no body, mind to go with it, there would be no awareness of the moon.

But the moon would still be there, correct?

How do you prove that? How do you validate that? How do you disprove that? How do you prove an unobserved phenomenon?

The moon is a human story. The universe is a human story. Its a human construct, or human experiences, and interpreted by the human mind.

So this would be akin to the question, which Im sure weve all heard, that if a tree falls in the forest and no one hears it, does it make a sound?

Correct. The sound is only in consciousness. Before that its a vibration of air molecules.

But the vibration of air molecules are occurring. Correct?

The vibration of air molecules is a human construct for a human mode of knowing and experience in human consciousness, so yes, they are constructs. The air molecules are as much of a construct as latitude and longitude, as The New Yorker, as Greenwich Mean Time, as money, as Wall Street, as Manhattan.

Im not sure what that means.

Human constructs are human ideas around modes of human knowing.

I see.

So an atom, a molecule, a force field, vibration of moleculesthese are all human constructs.

So its not that the tree is making a sound and we just happen to be there or not there to hear it. Its that the sound is only present to the degree that we are also present.

Actually, there is no tree and there is no sound and there is no body and there is no mind. Theres only consciousness thats having an experience. The rest is human constructs.

In your book Quantum Healing, you wrote, Research on spontaneous cures of cancer conducted in both the United States and Japan has shown that just before the cure appears, almost every patient experiences a dramatic shift in awareness. He knows that he will be healed and he feels that the force responsible is inside himself, but not limited to him. It extends beyond his personal boundaries throughout all of nature. Suddenly he feels, I am not limited to my body. All that exists around me is part of myself. At that moment, such patients apparently jumped to a new level of consciousness that prohibits the existence of cancer. Then the cancer cells either disappear, literally overnight in some cases, or at the very least stabilize without damaging the body any further.

So if you were a scientist and you saw one case of that, one in a billion, youd want to know the mechanism. And I feel the mechanism is a return to fundamental homeostasis, which means self-regulation, and total absence of fear, including the fear of death. Because your identity is no longer your body-mind.

And so is that more important than medicine?

No, I think medicine is very useful for acute illness. If you have pneumonia, I certainly tell you to take an antibiotic. You break your leg, Id have you see an orthopedic surgeon. If you have cancer, there are many types of chemotherapy and radiation and stem-cell therapies and immunotherapies that will help you. But, in todays age, if you dont understand that integrating that with good sleep, with meditation, with stress management, with mindfulness, with healthy emotions, with good food that actually changes the activity of your microbiomeif you dont conform to that, then youre out of date.

This is from your book Perfect Health: There exists in every person a place that is free from disease, that never feels pain, that cannot age or die. When you go to this place, limitations which all of us accept cease to exist. They are not even entertained as a possibility. This is the place called perfect health. Visits to this place may be very brief, or they may last for many years. Even the briefest visit, however, instills a profound change. As long as you are there, the assumptions that hold true for ordinary existence are altered. If you can be in this place, why would you necessarily need medicine to stay healthy?

We dont. Ive never used medicine myself. Im seventy-three years old, never been in the hospital, never had surgery. Cant even remember having a cold.

You would vaccinate your children, correct?

Of course I would, if Im in a surrounding where there is... You know, I would not vaccinate a child in New York City for polio, because it doesnt exist. But I would for measles, because it does exist.

Even if the child was in this state that you call perfect health?

The child is in a state of perfect health if its born normally. Its in a state of homeostasis. But we also live in a world that has environmental toxins, that has climate change, that has extinction of species, that has poison in our food chain, and that is ready for extinction. And all of that is the projection of our collective insanity.

You say, The cause of disease is often extremely complex, but one thing can be said for certain: no one has proved that getting sick is necessary.

Right. My own situation says that.

Because youve never been sick.

Yes.

Because youre in this place called perfect health?

Because Im aware of being aware and I can choose the experiences I want and I focus on love, compassion, joy, equanimity, and Im beyond the fear of personal death because I dont identify with my provisional, personal, so-called identity. The question you asked me when we started, How do you define yourself?I dont.

If we were all in this place, would we need medicine?

Yes. Because of the world weve created, we would, yes.

But not because

And, besides that, the ecosystem is a predatory play of consciousness where, you know, its a recycling of experience. Birth, death, illness: they are part of our provisional identity, but I dont identify with that identity. If you do not identify with the experience, if consciousness that is aware of experience, if the awareness of experience is not the experience, then youre intrinsically free of the experience. Do you know what Im saying?

Im not sure.

O.K. If you are aware of a thought, then youre not the thought, youre the awareness of the thought.

Dr. Stacia Kenet Lansman, whos a leading vaccine skeptic, cited your work as an inspiration. Do you

I have never been against vaccination.

I know you havent.

I have never spoken against medical treatment or intervention. You should do whatever works.

But do you worry that the idea that we can achieve this place of perfect health based on our own mental state can give license to anti-scientific thinking, like we see in the anti-vaccine movement?

You asked me if I worry about that. I dont worry about anything.

Which is why you havent gotten sick.

But people can take what I say and interpret it how they want to. Theres also a difference between scientism and science. Science is a very neutral activity: theories, observation, experiments, validation or invalidation. Period. I am a big proponent of science as the greatest adventure that human consciousness has taken. With scientism, its a different thing. Its being a fundamentalist and believing that science has all the solutions for human problems, including the existential dilemmas we have about our identity, our fear of old age, infirmity, and death.

There was an interview you gave many years ago, with Tony Robbins, about AIDS. Hed put forth the idea that H.I.V. is not the source of AIDS. You said, H.I.V. may be a precipitating agent in a susceptible host.The material agent is never the cause of the disease.It may be the final factor in inducing the full-blown syndrome in somebody whos already susceptible. He then asked,Butwhat made them susceptible? You answered, Their own interpretations of the whole reality that theyre participating in. Do you still feel that way about H.I.V. and AIDS?

I still feel that pathogens are precipitating factors in susceptible hosts, and that the outcome of illness and recovery is very complex. Now, having said that, when you can find a single agent that you can either attack or get rid of, then, of course, thats the solution. You know, you and I can be exposed to a pneumococcus and one person gets pneumonia and the other doesnt. So you can see that illness is not just one mechanistic happening, an encounter with the pathogen. It has to do with everything. Are you deeply rested, are you stressed, whats your nutrition, what are your personal relationships, what is your emotional stateall of these things have an influence. Every experience we have is ultimately metabolized into a molecule in the body. If I gave you bad news right now, your blood pressure would go up. In fact, if I sent a mean tweet to Mr. Trump, his blood pressure would go up even further.

You went on to say, I have a lot of patients with so-called AIDS, this label that weve given them, that are healthier than most of the population thats living in downtown Boston. They havent had a cold in ten years. And then Robbins said, But someone has told them they have this disease. You said, Yes, somebody has told them that. And Robbins says, And they bought into it. And you said, Exactly.

Listen. You can do a five-hour interviewyou can edit it into any way you want. You can take statements out of context.

No, thats the whole context.

And then you can say, This is what you said. Right? I had that experience myself as a physician. I said to the patient, You have cancer. Immediately, he looked like he was going to have a stroke. He was going to faint. And then I realized I read the wrong chart and I said, Sorry, that was somebody else. In two seconds I could see him recover from high blood pressure, sticky platelets, a jittery heart, and so on. So, you know, there is a lot more to reality than just a simple diagnosis and the label.

But to go on to the point youre just making now, about diagnosis, when Robbins said about the diagnosis of AIDS, People are accepting this, and when they accept this, what happens to them? You replied, When they accept it, then they make it happen. It is a self-fulfilling prophecy. Is that what youre saying?

Yeah. I might have said that. And, if I did, I regret it.

What I say today is, Believe the diagnosis, but dont believe the prognosis.

Youve been criticized before for selling products that people claim can help cure cancer or other diseases via meditation.

No, Ive never claimed that. No.

Never?

If you find a reference of that, let me know.

Well, there was a video called Return to Wholeness: A Mind-Body Approach to Healing Cancer. And the release about it says, Meditation and visualization are two of the most

Right. That video was a program to help people visualize and get into a relaxed state. I believe it was promoted as that on my Web site until I became aware of it, and then it was taken off.

And then you took it down?

Yeah. It was actually an artificial-intelligence program for meditation and self-regulation. And, by the way, used at many cancer-therapy clinics across the world as an aid to relaxation. [A member of Chopras staff named Cancer Treatment Centers of America as one of the clinics that use the video, but a representative for the treatment centers was unable to verify this.]

So, when you say in your best-sellers, like Super Brain, that increased self-awareness can reduce the risks of aging and help people achieve freedom and bliss, do you feel that youre doing that at all, or not?

I am. Of course. Im seventy-three years old, and I dont think my biological age is seventy-three. In fact, I have publicly declared that I am slowing down my aging process. And I think you can go on social media and look at all the pictures over the last few years and you can see, physically, that I am not looking as old, or feeling as old, as I was twenty-five years ago. I know what Ive said is outrageous, but, if people actually listen carefully, they will see that they determine a lot of what goes into well-being and health. And, ultimately, I dont think that health is physical at all. Because, ultimately, we are all going to die, and all going to have some kind of infirmity. But most of what we do is creating anxiety from living a full life in the present moment.

So you feel that youve reached a different stage of human existence?

Im just following the example of people who have lived long, healthy lives without any infirmity and died peacefully in meditation. In the Indian tradition, its called mahasamadhithe big meditation.

When youre selling books by saying that theres a network of intelligence in the human body that has the potential to defeat cancer, heart disease, and even aging itself, is that not selling to people that cancer can be beaten by something other than medicine?

Have you read the book? Or have you read criticisms of the book?

Ive read several of the books, and some criticisms.

So then you have to make up your own mind. Im not a purveyor of false hope. In fact, I think the term false hope is an oxymoron. Either you have hope or you dont. And those that have hope do better than those who dont.

So there is no false hope?

Its up to you how you interpret this, and it doesnt actually affect me. You know, Im at a stage in my life where Ive gone beyond criticism and/or flattery. I dont need that.

Go here to read the rest:
Deepak Chopra Has Never Been Sick - The New Yorker

Read More...

UCI professor named to CDC committee on sexually transmitted infections – Newswise

October 18th, 2019 6:44 pm

MEDIA CONTACT

Available for logged-in reporters only

Newswise Irvine, Calif. October 15, 2019 Sean Young, PhD, professor at the University of California Irvine School of Medicine and Donald Bren School of Information and Computer Sciences, has been appointed to the National Academies of Sciences, Engineering, and Medicine ad hoc committee to address the alarming increase in sexually transmitted infections (STIs). The Center for Disease Control (CDC) through the National Association of County and City Heath Officials requested the formation of the committee.

STIs have reached epidemic proportions nationally and continue to rise. Our committee is charged with investigating the problem and recommending novel and implementable solutions, said Young. Solutions exist. We are optimistic about the CDCs request for help that there will be resources and support to implement the committees solutions.

The Prevention and Control of Sexually Transmitted Infections in the United States committee will examine the epidemiological dimensions of STIs in the United States and factors that contribute to the epidemic (changes in population demographics, sexual and other behaviors, social determinants), as well as changes in the understanding of the agents that cause STIs.

Additionally, the study will attempt to address the economic burden associated with STIs and review current public health strategies and programs to prevent and control STIs (including STI diagnostics, STI vaccines, STI monitoring and surveillance, and treatment. Barriers in the healthcare system and insurance coverage associated with the prevention and treatment of STIs will also be surveyed.

Young was appointed to the committee due to his work at UCI leveraging social and behavioral data to detect real-world problems. He applied insights from psychology to online behavior change interventions and saw social norms could be modified.

Young uses this approach to transform time-consuming and expensive community-based interventions into online variants that more efficiently reach the masses. By analyzing peoples behaviors, problems from these behaviors can quickly be detected and addressed. Working with public health officials, Young is now developing tools that mine social data to identify potential areas of disease outbreak, crime, and poverty. His expertise will be used to address the STI epidemic.

We can now use technologies as a way of predicting and changing behavior, leading to positive and ethically delivered social change, said Young.

About the UCI School of Medicine: Each year, the UCI School of Medicine educates over 400 medical students, as well as 200 doctoral and masters students. More than 600 residents and fellows are trained at UC Irvine Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and masters degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/masters in public health, or an MD/masters degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visit som.uci.edu.

About the University of California, Irvine: Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 36,000 students and offers 222 degree programs. Its located in one of the worlds safest and most economically vibrant communities and is Orange Countys second-largest employer, contributing $5 billion annually to the local economy. For more on UCI, visit http://www.uci.edu.

See the rest here:
UCI professor named to CDC committee on sexually transmitted infections - Newswise

Read More...

Altru hosts Pretty in Pink, women’s health event at Red River High School – Grand Forks Herald

October 18th, 2019 6:44 pm

Altru Hospital is hosting its Pretty in Pink event in the commons of Red River High School from 6 to 8 p.m. Wednesday, Oct. 16.

The annual event is held by the hospital to celebrate Breast Cancer Awareness Month. The event is free and open to the public. Parking is available at the Cushman Field entrance. Attendees are asked to use door 1.

Beginning at 6 p.m., people can explore educational booths and community resources such as Womens Way, Breast Reconstruction Awareness, and get information about Altrus prosthetics and orthotics.

The evening will feature a little pampering as well, with free nail painting and chair massages, in an effort to bring community members together for the womens health awareness event.

People can sign up to win a bicycle donated by Scheels All Sports, and there is also a raffle with several prizes, as well as door prizes. All proceeds from the raffle go to Altrus Breast Cancer Coalition Fund, which seeks to help patients with breast health services not covered by insurance. All attendees will get a small gift to take home.

From 7 to 8 p.m., there will be presentations by breast cancer survivor Wendy Dahlberg, and Jen Haugen, supervisor of Integrative Medicine at Altru Health System.

More:
Altru hosts Pretty in Pink, women's health event at Red River High School - Grand Forks Herald

Read More...

Page 846«..1020..845846847848..860870..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick